A pharmacokinetic and pharmacodynamic study of valganciclovir in solid organ transplant patients

Not Applicable

• Conditions: Cytomegalovirus (CMV) infection; Infections and Infestations

• Registration Number: ISRCTN06404801
• Lead Sponsor: niversity Hospital Complex of Vaud (Centre Hospitalier Universitaire Vaudois [CHUV]) (Switzerland)

Brief Summary

2008 Thesis results in https://serval.unil.ch/resource/serval:BIB_E3D622D16963.P001/REF.pdf (added 19/07/2021)

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2007-02-14
• Study Completion: 2007-12-31
• Last Update Posted: 2 August 2021

Recruitment & Eligibility

• Sex: Not specified
• Target Recruitment: 100

Inclusion Criteria

1. Solid organ transplant recipient
2. More than or equal to 18 years old
3. At risk for CMV disease (D+/R-, D+/R+ or D-/R+)
4. Written informed consent

Exclusion Criteria

1. Failure to give written informed consent
2. Known intolerance to ganciclovir or valganciclovir

Study & Design

• Study Type: Observational
• Study Design: Not specified